BOSTON, Massachusetts – April 22nd, 2025 – Cycle Pharmaceuticals (Cycle) has launched Cycle Vita PKU, an AI-powered app to help patients with PKU manage every aspect of their treatment plan. 

PKU is an inherited disorder caused by a deficiency of the phenylalanine hydroxylase (PAH) enzyme needed to process phenylalanine (Phe), which is found in all foods containing protein.1 Nearly all cases of PKU are diagnosed through newborn screenings,2 and require lifelong adherence to a strict PKU diet.3 

It can be challenging for patients with PKU, or their caregivers, to keep on top of everything, like medication, medical formula, lab results and diet. The app is designed to offer flexible and timely support with daily tracking, reminders and diet management tools. Users can plan their meals with a searchable food database of over 9,000 foods, as well as an AI-powered meal scanner that estimates Phe levels with a photo snap of the meal. 

For adolescents and young adults, who are gaining independence and navigating the transition to adulthood, Cycle Vita PKU may be a helpful aid for adhering to their medication and a Phe-restricted diet on-the-go. 

“The launch of Cycle Vita PKU marks an exciting milestone as the first app from Cycle Vita™, Cycle’s dedicated patient support platform. As part of Cycle’s commitment to the PKU community, Cycle will continue to innovate and find new ways to provide support tailored to patients’ needs. Cycle Vita PKU is just one example of that commitment.” says Jamie Ray, Director – Patient Support Program, Cycle. 

Cycle Vita PKU does not provide medical advice, diagnosis or treatment. Always seek the advice of your healthcare provider with any questions you may have. 

References 

  1. National Institutes of Health. 2024. Phenylketonuria (PKU). Available at: https://www.nichd.nih.gov/health/topics/pku. [Accessed January 22nd 2025]
  2. National Institutes of Health. 2024. How do health care providers diagnose phenylketonuria (PKU)? Available at: https://www.nichd.nih.gov/health/topics/pku/conditioninfo/diagnosed. [Accessed January 22nd 2025]
  3. National Institutes of Health. 2024. What are common treatments for phenylketonuria (PKU)? Available at: https://www.nichd.nih.gov/health/topics/pku/conditioninfo/treatments. [Accessed January 22nd 2025] 

-ENDS-

Cycle Vita™ and Cycle Vita PKU™ are trademarks of Cycle Pharmaceuticals Ltd. 

©2025 Cycle Pharmaceuticals Limited. All rights reserved. 

US-VITA-2500003. February 2025 

About Cycle Pharmaceuticals

Cycle Pharmaceuticals was founded in 2012 with the sole aim of delivering drug treatments and product support to the underserved rare disease patient community. Cycle focuses on rare metabolic, immunological, and neurological genetic conditions. Within neurological conditions, we focus on multiple sclerosis. Cycle is headquartered in Cambridge, UK and has offices in Boston, Massachusetts. For more information, please visit www.cyclepharma.com and follow us on X, LinkedIn and Facebook.

FOR FURTHER INFORMATION PLEASE CONTACT

Marketing@cyclepharma.com
Cycle Pharmaceuticals
Tel: +44 1223 354 118

Cycle Pharma Logo Light

CYCLE Pharmaceuticals Limited is registered in England and Wales. Registration number 07933058.

Modern Slavery Statement
Head Office (UK)

Cycle Pharmaceuticals Ltd
The Broers Building
21 JJ Thomson Ave
Cambridge, CB3 0FA
United Kingdom

+44 1223 354118

US Office

Cycle Pharmaceuticals Inc.
19 Clifford St
Detroit, MI 48226
United States

+1 800 903 1793

US Office

Cycle Pharmaceuticals Inc.
200 Portland St
Boston, MA 02114
United States

+1 800 903 1793

© 2026 Cycle Pharmaceuticals Limited. All rights reserved.

GL-CC-2500026 | June 2025

Follow us